EUVIMEDEUVIMED entdecken
Crossref

Shortening the biologics clinical timeline with a novel method for generating stable, high‐producing cell pools and clones

Chad A Hall, Rachel H Kravitz, Karl F Johnson, Nicholas A Sanek, Payel Maiti, Keith R Ziemba, Jia Liu, Dmitri O Andreev, Victoria L Chrostowski, Ian J Collins, Gregory T Bleck

Biotechnology and Bioengineering · 2025

DOI: 10.1002/bit.28323 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology and Bioengineering, 2025. Verfasst von Chad A Hall und 10 weiteren Autor:innen. Beteiligte Einrichtung: Catalent Pharma Solutions, Somerset, New Jersey, USA. Hauptthemen laut MEDLINE: Biological Products. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reducing drug development timelines is an industry‐wide goal to bring medicines to patients in need more quickly. This was exemplified in the coronavirus disease 2019 pandemic where reducing development timelines had a direct impact on the number of lives lost to the disease. The use of drug substances produced using cell pools, as opposed to clones, has the potential to shorten development timelines. Toward this goal, we have developed a novel technology, GPEx® Lightning, that allows for rapid, reproducible, targeted recombination of transgenes into more than 200 Dock sites in the Chinese hamster ovary cell line genome. This allows for rapid production of high‐expressing stable cell pools and clones that reach titers of 4–12 g/l in generic fed‐batch production. These pools and clones are highly stable in both titer and glycosylation, showing strong similarities in glycosylation profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsCHO CellsCricetulusAnimalsCOVID-19HumansGlycosylationSARS-CoV-2CricetinaeBatch Cell Culture Techniques

Stichwörter der Autor:innen

CHO cellscell poolsexpressionsite‐specific recombination

Substanzen

Biological Products

Autor:innen und Institutionen

  • Catalent Pharma Solutions, Somerset, New Jersey, USA.

Zitieren

APA

Hall, C. A., Kravitz, R. H., Johnson, K. F., Sanek, N. A., Maiti, P., Ziemba, K. R., Liu, J., Andreev, D. O., Chrostowski, V. L., Collins, I. J., & Bleck, G. T. (2025). Shortening the biologics clinical timeline with a novel method for generating stable, high‐producing cell pools and clones. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28323

Vancouver

Hall CA, Kravitz RH, Johnson KF, Sanek NA, Maiti P, Ziemba KR, et al. Shortening the biologics clinical timeline with a novel method for generating stable, high‐producing cell pools and clones. Biotechnology and Bioengineering. 2025. doi:10.1002/bit.28323

BibTeX
@article{Hall2025,
  author = {Hall, Chad A and Kravitz, Rachel H and Johnson, Karl F and Sanek, Nicholas A and Maiti, Payel and Ziemba, Keith R and Liu, Jia and Andreev, Dmitri O and Chrostowski, Victoria L and Collins, Ian J and Bleck, Gregory T},
  title = {Shortening the biologics clinical timeline with a novel method for generating stable, high‐producing cell pools and clones},
  journal = {Biotechnology and Bioengineering},
  year = {2025},
  doi = {10.1002/bit.28323}
}
Kostenlos starten →